Results for Combination Bevacizumab Plus Mirvetuximab Soravtansine in Ovarian Cancer

David O'Malley, MD

David O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.

David O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab (Avastin) plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.

There is still not enough data to say there is synergy between these 2 agents, but so far there has been an increase in progression-free survival (PFS) and response rates compared to standard cytotoxic chemotherapies.